---
title: "Pulmonary artery growth after PDA stent versus modified Blalock–Taussig shunt in ductal-dependent"
id: "plos-one-20-comparative-outcomes-of-pulmonary-artery-changes-in-ductal-patency-dependent"
canonical_url: "https://medichelpline.com/clinical-feed/plos-one-20-comparative-outcomes-of-pulmonary-artery-changes-in-ductal-patency-dependent"
content_type: "clinical_feed_article"
specialty: "Cardiology"
source_name: "PLOS ONE (Medicine)"
source_url: "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0358266"
published_at: "2026-09-15T14:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Pulmonary artery growth after PDA stent versus modified Blalock–Taussig shunt in ductal-dependent
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/plos-one-20-comparative-outcomes-of-pulmonary-artery-changes-in-ductal-patency-dependent
- **Specialty:** [Cardiology](https://medichelpline.com/clinical-feed/cardiology.md)
- **Primary Source:** PLOS ONE (Medicine)
- **Source URL:** [Original Journal Publication](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0358266)
- **Published At:** 2026-09-15T14:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This multicenter retrospective cohort study compared pulmonary artery (PA) growth, procedural complications, and mortality in neonates with ductal-dependent pulmonary blood flow (DP-PBF) who underwent **patent ductus arteriosus (PDA) stenting** versus **modified Blalock–Taussig shunt (mBTS)** as first-stage palliation. - The study included 86 infants treated between January 2017 and December 2022 at two tertiary centers in Thailand: 41 received PDA stents and 45 underwent mBTS. Baseline PA measurements were reported as comparable between groups, although diagnostic composition differed. - PA growth was quantified using the **McGoon ratio** and **Nakata index** at baseline, 2 months, and 12 months. Left-to-right PA diameter symmetry (LPA/RPA) was also assessed. - At 2 months, PDA stenting was associated with greater PA growth: higher McGoon ratio (mean difference 0.18; 95% CI 0.05–0.31; p = 0.005) and higher Nakata index (mean difference 51.2 mm2/m2; 95% CI 23.0–79.5; p < 0.001) compared with mBTS. - By 12 months, Nakata index values were similar between the two groups (p = 0.90), while a statistically significant difference in McGoon ratio persisted favoring PDA stenting (mean difference 0.15; 95% CI 0.02–0.29; p = 0.028). - Procedural complications were less frequent after PDA stenting (17.1%) than after mBTS (57.8%); the risk ratio for complications with mBTS versus PDA stenting was 3.38 (95% CI 1.65–6.95; p = 0.001). - Mortality was numerically lower after PDA stenting, but time-to-event analyses (Kaplan–Meier, Cox regression, and 12-month restricted mean survival time) showed no statistically significant survival difference between groups. - The authors caution interpretation due to non-randomized treatment allocation, differing diagnostic composition between groups, and potential residual confounding. Details on specific diagnoses, procedural techniques, and full complication breakdowns were reported in the source article but are not fully restated here.
## Clinical Analysis & Structured Key Points
Comparative outcomes of pulmonary artery changes in ductal-patency-dependent pulmonary circulation: Patent ductus arteriosus stent versus modified Blalock–Taussig shunt | PLOS One Browse Subject Areas ? Click through the PLOS taxonomy to find articles in your field. For more information about PLOS Subject Areas, click here . Article Authors Metrics Comments Media Coverage Peer Review Reader Comments Figures Figures Abstract Background Neonates with ductal-dependent pulmonary blood flow (DP-PBF) require timely palliation to maintain pulmonary perfusion. Patent ductus arteriosus (PDA) stenting has emerged as a less invasive alternative to modified Blalock–Taussig shunt (mBTS), but comparative data on longitudinal pulmonary artery growth and clinical outcomes remain limited. Methods This multicenter retrospective cohort study included infants with DP-PBF who underwent PDA stenting or mBTS as first-stage palliation at Queen Sirikit National Institute of Child Health and Songklanagarind Hospital, Thailand, between January 2017 and December 2022. Pulmonary artery growth was assessed using the McGoon ratio and Nakata index at baseline, 2 months, and 12 months. Longitudinal changes were analyzed using linear mixed-effects models with adjustment for ventricular physiology. Procedural complications were compared, and mortality was evaluated using Kaplan–Meier analysis, Cox regression, and 12-month restricted mean survival time. Results Eighty-six infants were included: 41 underwent PDA stenting and 45 underwent mBTS. Baseline pulmonary artery measurements were comparable, although diagnostic composition differed between groups. At 2 months, PDA stenting was associated with greater pulmonary artery growth than mBTS, with a higher McGoon ratio (mean difference, 0.18; 95% CI, 0.05–0.31; p = 0.005) and Nakata index (mean difference, 51.2 mm 2 /m 2 ; 95% CI, 23.0–79.5; p < 0.001). By 12 months, the Nakata index was similar between groups (p = 0.90), whereas a statistically significant between-group difference in McGoon ratio remained (mean difference, 0.15; 95% CI, 0.02–0.29; p = 0.028). Procedural complications were less frequent after PDA stenting than after mBTS (17.1% vs 57.8%; risk ratio for mBTS vs PDA stenting, 3.38; 95% CI, 1.65–6.95; p = 0.001). Although mortality was numerically lower after PDA stenting, time-to-event analyses did not show a statistically significant survival difference. Conclusions In this cohort, PDA stenting was associated with greater early pulmonary artery growth and fewer observed procedural complications compared with mBTS. By 12 months, the Nakata index was similar between groups, whereas a statistically significant difference in McGoon ratio remained. These findings should be interpreted cautiously because of non-randomized treatment allocation, differences in diagnostic composition, and potential residual confounding. Citation: Patrakunwiwat P, Pattharasripong K, Wongwaitaweewong K, Roymanee S, Promphan W, Jarutach J, et al. (2026) Comparative outcomes of pulmonary artery changes in ductal-patency-dependent pulmonary circulation: Patent ductus arteriosus stent versus modified Blalock–Taussig shunt. PLoS One 21(9): e0358266. https://doi.org/10.1371/journal.pone.0358266 Editor: Atnafu Mekonnen Tekleab, St Paul’s Hospital Millennium Medical College, ETHIOPIA Received: March 31, 2026; Accepted: August 28, 2026; Published: September 15, 2026 Copyright: © 2026 Patrakunwiwat et al. This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability: The study dataset cannot be made publicly available because public sharing was not included in the ethics approvals granted by the participating institutions. Although the datasets used for analysis were anonymized and the investigators had no access to directly identifying participant information, the data remain subject to institutional and ethical data-sharing requirements. De-identified data may be made available to qualified researchers upon reasonable request, subject to approval by the relevant institutional research ethics committee(s) and applicable institutional data-sharing requirements. Requests for data access may be directed to the Human Research Ethics Unit, Faculty of Medicine, Prince of Songkla University, Thailand (Tel: +66 74 451157 or +66 74 451149; Email: medpsu.ec@gmail.com ; Website: https://hrec.medicine.psu.ac.th ). The anonymized study dataset will be securely retained in access-controlled institutional data storage at the Faculty of Medicine, Prince of Songkla University, in accordance with applicable institutional policies and research ethics requirements to support long-term preservation and availability. Funding: The author(s) received no specific funding for this work. Competing interests: The authors have declared that no competing interests exist. Introduction Congenital heart disease affects approximately 8–10 per 1,000 live births [ 1 , 2 ]. In neonates with ductal patency-dependent pulmonary blood flow (DP-PBF), continuous prostaglandin E1 infusion is commonly used to maintain ductal flow, supporting oxygenation until definitive repair or staged reconstruction [ 3 ]. First-stage palliation is therefore undertaken to secure adequate pulmonary perfusion during this interval. Beyond short-term stabilization, a major objective of initial palliation is to promote branch pulmonary artery (PA) growth, as PA dimensions influence the feasibility and complexity of subsequent interventions. The modified Blalock–Taussig systemic-to-pulmonary shunt (mBTS) has traditionally been a standard palliative approach to secure pulmonary blood flow, but it can be associated with operative and postoperative morbidity, including recurrent laryngeal or phrenic nerve injury and thoracic complications such as hemothorax, pneumothorax, and chylothorax [ 4 , 5 ]. Patent ductus arteriosus stenting (PDAs) is a catheter-based alternative to mBTS for initial palliation, offering shorter hospitalization and avoidance of surgery, although stent-specific adverse events, including ductal dissection or rupture, stent thrombosis, stent embolization/migration, and potential branch PA compromise, remain important concerns [ 6 , 7 ]. To date, the comparative literature has not established definitive superiority of PDAs over mBTS with respect to PA growth, a key benchmark for first-stage palliation in neonates with DP-PBF. Although both strategies may promote PA development, the relative contribution of ductal flow-mediated hemodynamics versus surgically created systemic-to-pulmonary shunting remains incompletely defined, and comprehensive head-to-head quantitative data are limited. Quantitative assessment of PA development is routinely performed during follow-up using established echocardiograms and angiographic indices. The McGoon ratio is defined as the sum of the prebranching diameters of the right and left PAs to the diameter of the descending aorta at the level of the diaphragm, providing an estimate of PA adequacy relative to systemic arterial size [ 8 ]. The Nakata index provides a complementary assessment by expressing PA size as the combined cross-sectional area of the right and left PAs normalized to body surface area, with areas derived from measured diameters assuming circular geometry [ 9 ]. Together, these complementary metrics provide a structured framework for comparing PA growth following PDAs versus mBTS in neonates with DP-PBF. The primary objective of this study was to compare pulmonary artery growth between neonates undergoing PDA stenting and those undergoing mBTS for ductal patency-dependent pulmonary blood flow. Secondary objectives were to compare procedural complications and mortality between the two treatment strategies. Methods Study design and setting We conducted a multicenter retrospective cohort study including neonates with DP-PBF treated between January 2017 and December 2022 at Queen Sirikit National Institute of Child Health (QSNICH) and Songklanagarind Hospital, Thailand. The study was approved by the institutional ethics committees of both centers (Songklanagarind Hospital: REC.66-499-1-1; Queen Sirikit National Institute of Child Health: REC.070/2567) and conducted in accordance with the Declaration of Helsinki. Data were accessed for research purposes at Songklanagarind Hospital on 01/01/2024 and at Queen Sirikit National Institute of Child Health (QSNICH) on 01/08/2024, following complete anonymization of all datasets. Throughout the study period, the authors had no access to any information that could identify individual participants. Study population Infants aged <60 days with DP-PBF who underwent first-stage palliation with either a PDA or mBTS were eligible. Patients were excluded from longitudinal growth analyses if they crossed over to an alternative treatment modality after the index procedure or had incomplete PA measurements at the specified follow-up time points. However, all patients undergoing the index procedure were included in analyses of procedural complications and mortality. Data collection and follow-up Baseline demographic and clinical variables were systematically extracted from medical records, including sex, body weight, body length, oxygen saturation, cardiac diagnosis, chromosomal abnormalities, and baseline PA dimensions. PA growth was assessed using the McGoon ratio and Nakata index at baseline, 2 months, and 12 months after the procedure. Branch PA symmetry was evaluated using the left-to-right PA diameter ratio (LPA/RPA) at the same time points. Procedural selection and techniques The choice between PDA stenting and mBTS was determined by the multidisciplinary treating team in accordance with institutional practice, patient anatomy, ventricular physiology, ductal morphology, and procedural feasibility. PDA stenting was generally considered for patients with ductal anatomy suitable for transcatheter intervention, whereas mBTS was preferred in patients with univentricular physiology, markedly tortuous ducts, or any anatomical variation considered unsuitable or high risk for stent implantation. PDA stenting was performed under general anesthesia using standard transcatheter techniques as previously described [ 6 ]. Prostaglandin E1 was discontinued for 6–8 hours before the procedure ( Fig 1 ). Ductal anatomy and its relationship to the branch pulmonary arteries were assessed angiographically. A coronary guidewire was advanced across the ductus into a distal pulmonary artery branch, followed by balloon preparation when needed and coronary stent deployment under fluoroscopic guidance. Final angiography confirmed ductal coverage and assessed for branch pulmonary artery compromise. Download: PNG larger image TIFF original image Fig 1. Representative angiographic images from a patient included in the study with pulmonary atresia and intact ventricular septum. (A) Aortography shows a patent ductus arteriosus with a 2-mm pulmonary artery end, 4.4-mm ampulla, and 10-mm length. (B) The ductus is crossed retrogradely with a 0.014-inch guidewire. (C) A Resolute Onyx 4.5 × 15 mm coronary stent is deployed. (D) Completion angiography confirms appropriate stent position without complications. https://doi.org/10.1371/journal.pone.0358266.g001 mBTS was performed using a polytetrafluoroethylene graft anastomosed between the innominate or subclavian artery and the main or branch of the pulmonary artery, with graft size selected based on patient body weight and vessel size. Post-procedural antithrombotic therapy was administered according to institutional practice. Post-procedural antithrombotic therapy was administered according to institutional practice. Patients undergoing PDA stenting received intravenous heparin for at least 24 hours after the procedure, followed by dual antiplatelet therapy with aspirin and clopidogrel for 6 months. Thereafter, aspirin monotherapy was continued until definitive surgical repair or the next-stage palliation. In contrast, patients undergoing mBTS received intravenous heparin for at least 24 hours postoperatively, followed by aspirin monotherapy at 3–5 mg/kg/day until definitive surgical repair or the next-stage palliation. Outcomes The primary outcome was PA growth, assessed by changes in McGoon ratio and Nakata index at 2 and 12 months. Secondary outcomes included procedural complications and all-cause mortality. Sample size estimation Sample size was estimated for the primary outcome of pulmonary artery growth, assessed by the Nakata index. Using a two-independent-means formula with a two-sided test, prior reference data reported mean Nakata indices of 162 ± 26 and 194.7 ± 48 in infants undergoing ductal stenting and surgical shunting, respectively [ 10 ]. Assuming a two-sided alpha level of 0.05, 80% power, and a 2:1 allocation ratio, the required sample size was 41 patients. After accounting for approximately 10% incomplete data, the final estimated sample size was 46 patients. Statistical analysis Categorical variables are presented as frequencies and percentages and were compared using the χ² test or Fisher’s exact test, as appropriate. Continuous variables were assessed for approximate normality and are presented as mean ± standard deviation (SD). Between-group comparisons of continuous variables were performed using two-sided independent-samples t tests. Diagnosis distributions were compared using the χ² test. Differences in PA indices across diagnostic categories were evaluated using two-sided one-way analysis of variance (ANOVA) at baseline and 12 months, with Bonferroni-adjusted post hoc comparisons. For longitudinal assessment of PA growth, the McGoon ratio and Nakata index were compared between the PDAs and mBTS groups at each prespecified time point (baseline, 2 months, and 12 months) using linear mixed-effects (random-intercept) models, with treatment group, follow-up time, and their interaction as fixed effects and a random intercept for each patient. This repeated-measures approach used all available observations under a missing-at-random assumption, thereby accommodating incomplete follow-up without restricting the complete cases. Between-group differences (PDAs minus mBTS) at each time point were estimated as model-based linear contrasts and reported with 95% confidence intervals; the overall group-by-time interaction was tested with a likelihood-ratio test. To address potential confounding by indication, the longitudinal models were repeated with additional adjustment for ventricular physiology (biventricular vs univentricular) and its interaction with time. Analyses of branch pulmonary artery symmetry (LPA/RPA ratio) were performed among patients with available measurements at each time point. Procedural complications and mortality were compared using the χ² test. Risk ratios (RRs) with 95% confidence intervals (CIs) were calculated to quantify the relative risk associated with mBTS compared with PDAs. Mortality was evaluated descriptively and using time-to-event analyses. Overall survival was defined as the time from the index procedure to death from any cause or censoring at the last documented follow-up. Because the index procedure date, date of death, and censoring or last follow-up date were available, Kaplan–Meier curves were generated and compared using the log-rank test. Cox proportional hazards models were used to estimate hazard ratios for mortality, with additional adjustment for ventricular physiology. The proportional hazards assumption was assessed before Cox regression. Restricted mean survival time was calculated up to 12 months to summarize survival over the prespecified follow-up interval. To further evaluate potential confounding due to differential diagnostic composition and loss to follow-up, sensitivity analyses were performed restricting the cohort to patients with complete longitudinal data and stratifying by ventricular physiology. The direction and magnitude of between-group differences were compared with the primary analysis to assess consistency. All analyses were conducted using Stata version 19.5 (StataCorp LLC, College Station, TX, USA). A two-sided p-value < 0.05 was considered statistically significant. Results A total of 86 infants with DP-PBF were included; 45 received an mBTS, and 41 underwent PDAs as first-stage palliation. During follow-up, attrition in the mBTS group was due to mortality (n = 12), loss to follow-up (n = 2), and conversion to an alternative treatment modality (n = 1), leaving 30 patients with complete follow-up. In the PDAs group, attrition was due to mortality (n = 2), loss to follow-up (n = 7), and conversion to an alternative treatment modality (n = 2), resulting in 30 patients with complete follow-up for the final analysis ( Fig 2 ). Download: PNG larger image TIFF original image Fig 2. Initial surgical and interventional strategies for duct patency-dependent pulmonary blood flow. https://doi.org/10.1371/journal.pone.0358266.g002 Table 1 presents baseline characteristics of the 86 infants with DP-PBF included in the analysis. The proportion of male infants was similar between groups. Mean weight was comparable, whereas mean body height was greater in the PDAs group (p = 0.002). Baseline oxygen saturation did not differ significantly between groups. Chromosomal abnormalities were infrequent and comparable between the two groups. The distribution of underlying diagnoses differed between groups ( p < 0.001), with univentricular heart disease more frequent in the MBTs group and pulmonary atresia with an intact ventricular septum more frequent in the PDAs group; pulmonary atresia with a ventricular septal defect and Tetralogy of Fallot were less common in both groups. Baseline PA measurements were similar, including LPA diameter, RPA diameter, McGoon ratio, and Nakata index. Download: PNG larger image TIFF original image Table 1. Comparative characteristics of patients in the PDAs and mBTS groups. https://doi.org/10.1371/journal.pone.0358266.t001 Baseline diagnostic composition differed between procedural groups ( p < 0.001). The McGoon ratio did not differ across diagnostic categories at baseline (one-way ANOVA: F (3,82) = 0.47, p = 0.7038) or at 12 months (F (3,63) = 2.31, p = 0.0847); Bonferroni-adjusted pairwise comparisons were not statistically significant (baseline: all adjusted p = 1.000; 12 months: all adjusted p ≥ 0.073). Similarly, the Nakata index did not differ across diagnostic categories at baseline (F (3,81) = 1.15, p = 0.3345) or at 12 months (F (3,63) = 0.57, p = 0.6374), with no significant Bonferroni-adjusted post hoc differences (baseline: all adjusted p ≥ 0.540; 12 months: all adjusted p = 1.000). Pulmonary artery growth was evaluated using the McGoon ratio and Nakata index at baseline, 2 months, and 12 months after PDA stenting or mBTS ( Fig 3 and Table 2 ). The mean McGoon ratio was 1.450 ± 0.285 at baseline. At baseline, the model-based between-group difference, calculated as PDA stenting minus mBTS, was −0.01 (95% CI, −0.13 to 0.11; p = 0.84). At 2 months, the mean McGoon ratio was 1.721 ± 0.325 in the PDA stenting group and 1.540 ± 0.194 in the mBTS group, with a model-based between-group difference of 0.18 (95% CI, 0.05 to 0.31; p = 0.005). At 12 months, the mean McGoon ratio was 2.080 ± 0.323 in the PDA stenting group and 1.930 ± 0.334 in the mBTS group, with a model-based between-group difference of 0.15 (95% CI, 0.02 to 0.29; p = 0.028). The longitudinal change in the McGoon ratio differed between treatment groups (likelihood-ratio p = 0.018). After adjustment for ventricular physiology, the corresponding between-group differences were 0.00 at baseline (95% CI, −0.12 to 0.13; p = 0.97), 0.19 at 2 months (95% CI, 0.06 to 0.32; p = 0.005), and 0.16 at 12 months (95% CI, 0.02 t
## Related Clinical Research

- [Using Large Language Models to Detect Acute Coronary Syndrome Management Delays](https://medichelpline.com/clinical-feed/pubmed-42259441.md) (DOI: 10.1016/j.amjcard.2026.05.031)
- [Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta‐Analysis](https://medichelpline.com/clinical-feed/journal-of-the-american-heart-association-21-optimal-antithrombotic-therapy-for-peripheral-artery-disease-a-systematic.md)
- [Cost-effectiveness of rivaroxaban plus aspirin in COMPASS: a Scandinavian lifetime analysis](https://medichelpline.com/clinical-feed/pubmed-42700109.md) (DOI: 10.1080/14017431.2026.2728343)
- [Heparin-induced thrombocytopenia during therapeutic plasma exchange in neuromyelitis optica: singl](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-case-report-confirmed-and-suspected-heparin-induced-thrombocytopenia-during.md)
- [Young-onset stroke in the UAE: risk factors, subtypes, and outcomes from a single-centre study](https://medichelpline.com/clinical-feed/plos-one-19-young-onset-stroke-in-the-uae-a-single-centre-retrospective-analysis-of-risk.md)

## Navigation
- [← Back to Cardiology Feed](https://medichelpline.com/clinical-feed/cardiology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.